Are you willing to invest in Biocept (BIOC)?
What’s up with Biocept?
Biocept (BIOC) opened at $0.41, which means the stock is down 3.83% from yesterday’s closing price of 0.40. Today, the company has a high of $0.41 and a low of $0.39. The company has a market cap of $50.44 million with a 52-week high of $2.11 and a 52-week low of $0.21.
What about the future for Biocept?
The high forecast for Biocept is 1.00 while the low is 0.20. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Biocept has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy. Based on this information BIOC seems to be a risky buy.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.